Do bioresorbable vascular scaffolds improve clinical outcomes compared to everolimus-eluting stents in patients with coronary artery disease?
A meta-analysis suggests bioresorbable vascular scaffolds are associated with worse 2-year clinical outcomes compared to everolimus-eluting stents in CAD.
BRS may be associated with worse two-years clinical outcomes compared with EES in patients with coronary artery disease.
Polimeni et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: